These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. [New pharmacologic aspects in the neurologic profile of propentofylline (Karsivan ad us. vet.)]. Kapl D; Rudolphi KA Tierarztl Prax Ausg K Kleintiere Heimtiere; 1998 Sep; 26(5):317-21. PubMed ID: 9931990 [TBL] [Abstract][Full Text] [Related]
47. Dementia three months after stroke. Baseline frequency and effect of different definitions of dementia in the Helsinki Stroke Aging Memory Study (SAM) cohort. Pohjasvaara T; Erkinjuntti T; Vataja R; Kaste M Stroke; 1997 Apr; 28(4):785-92. PubMed ID: 9099197 [TBL] [Abstract][Full Text] [Related]
48. Reliability of NINDS-AIREN clinical criteria for the diagnosis of vascular dementia. Lopez OL; Larumbe MR; Becker JT; Rezek D; Rosen J; Klunk W; DeKosky ST Neurology; 1994 Jul; 44(7):1240-5. PubMed ID: 8035923 [TBL] [Abstract][Full Text] [Related]
49. Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). Wetterling T; Kanitz RD; Borgis KJ Stroke; 1996 Jan; 27(1):30-6. PubMed ID: 8553399 [TBL] [Abstract][Full Text] [Related]
51. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Román GC; Tatemichi TK; Erkinjuntti T; Cummings JL; Masdeu JC; Garcia JH; Amaducci L; Orgogozo JM; Brun A; Hofman A Neurology; 1993 Feb; 43(2):250-60. PubMed ID: 8094895 [TBL] [Abstract][Full Text] [Related]
52. Propentofylline treatment for Alzheimer disease and vascular dementia: an economic evaluation based on functional abilities. Bachynsky J; McCracken P; Lier D; Alloul K; Jacobs P Alzheimer Dis Assoc Disord; 2000; 14(2):102-11. PubMed ID: 10850749 [TBL] [Abstract][Full Text] [Related]
53. Study protocol for a phase III randomised controlled trial of Sailuotong (SLT) for vascular dementia and Alzheimer's disease with cerebrovascular disease. Karamacoska D; Chan DKY; Leung I; Liu JX; Brodaty H; Fahey PP; Bensoussan A; Chang DH PLoS One; 2023; 18(3):e0265285. PubMed ID: 36920949 [TBL] [Abstract][Full Text] [Related]
54. The profile of behavioral and psychological symptoms in vascular cognitive impairment with and without dementia. Gupta M; Dasgupta A; Khwaja GA; Chowdhury D; Patidar Y; Batra A Ann Indian Acad Neurol; 2013 Oct; 16(4):599-602. PubMed ID: 24339588 [TBL] [Abstract][Full Text] [Related]
56. HWA 285 (propentofylline)--a new compound for the treatment of both vascular dementia and dementia of the Alzheimer type. Rother M; Kittner B; Rudolphi K; Rössner M; Labs KH Ann N Y Acad Sci; 1996 Jan; 777():404-9. PubMed ID: 8624121 [TBL] [Abstract][Full Text] [Related]
57. Single stroke dementia: insights from 12 cases in Singapore. Auchus AP; Chen CP; Sodagar SN; Thong M; Sng EC J Neurol Sci; 2002 Nov; 203-204():85-9. PubMed ID: 12417363 [TBL] [Abstract][Full Text] [Related]
58. Validity of the clinical diagnostic criteria for vascular dementia: a critical review. Part II. Wiederkehr S; Simard M; Fortin C; van Reekum R J Neuropsychiatry Clin Neurosci; 2008; 20(2):162-77. PubMed ID: 18451187 [TBL] [Abstract][Full Text] [Related]
59. Glial modulating and neurotrophic properties of propentofylline and its application to Alzheimer's disease and vascular dementia. Ringheim GE Ann N Y Acad Sci; 2000 Apr; 903():529-34. PubMed ID: 10818548 [No Abstract] [Full Text] [Related]
60. Propentofylline: glial modulation, neuroprotection, and alleviation of chronic pain. Sweitzer S; De Leo J Handb Exp Pharmacol; 2011; (200):235-50. PubMed ID: 20859798 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]